In this brief commentary, the speaker outlines the prevailing view among tumor biologists that inhibiting glutathione could weaken cancer cells, but notes that real‑world clinical attempts to block glutathione have fallen short of expectations. Moreover, emerging research indicates that some cancer cells become more resistant to therapy when they are glutathione‑deficient, highlighting a paradox where the intended strategy may backfire.
If you look at tumor biologists, they will say, well, certainly there is this idea that if we could block glutathione, we would take away the strength of some of these cancer cells. Glutathione blockade as an actual treatment in clinical practice, so not in research, but actually in the average human, is not as rewarding as we thought it was. And then there's also research that shows that there's other cancer cells that when they become deficient in glutathione, they're actually more treatment resistant as well.
